
<rdf:RDF xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:svcs="http://rdfs.org/sioc/services#" xmlns:doap="http://usefulinc.com/ns/doap#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  
<ore:Aggregation rdf:about="https://phaidra.vetmeduni.ac.at/o:4046/#Aggregation">
  
<edm:aggregatedCHO rdf:resource="https://phaidra.vetmeduni.ac.at/o:4046"></edm:aggregatedCHO>

  
<edm:dataProvider>University of Veterinary Medicine Vienna</edm:dataProvider>

  
<edm:isShownAt rdf:resource="https://phaidra.vetmeduni.ac.at/o:4046"></edm:isShownAt>

  
<edm:isShownBy rdf:resource="https://phaidra.vetmeduni.ac.at/api/object/o:4046/get"></edm:isShownBy>

  
<edm:object rdf:resource="https://phaidra.vetmeduni.ac.at/api/object/o:4046/thumbnail"></edm:object>

  
<edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc-nd/4.0/"></edm:rights>

  
</ore:Aggregation>

  
<edm:ProvidedCHO rdf:about="https://phaidra.vetmeduni.ac.at/o:4046">
  
<dc:title xml:lang="en">YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells</dc:title>

  
<dc:description xml:lang="en">Ewing sarcoma (EwS) is an aggressive cancer of adolescents in need of effective treatment. Insulin-like growth factor (IGF)-1 is an autocrine growth factor for EwS, but only 10% of patients respond to IGF-1 receptor (IGF-1R) blockade. Although EwS is presumed to originate from mesenchymal progenitors during bone development, targeting of the EwS driver oncogene EWS::FLI1 to the mesenchymal lineage in a mouse model does not result in tumor formation but in skeletal malformations and perinatal death. We report that transient exposure to IGF-1 concentrations mimicking serum levels during puberty reprograms limb-derived mesenchymal cells of EWS::FLI1-mutant mice to stable transformation and tumorigenicity. We identify a modular mechanism of IGF-1-driven tumor promotion in the early steps of EwS pathogenesis, in which Yap1 plays a central role. Pharmacologic Yap1/Tead inhibition reverses the transformed phenotype of EWS::FLI1-expressing cells. Our data provide a rationale for combined IGF-1R and YAP/TEAD inhibition in the treatment of EwS patients.</dc:description>

  
<dc:identifier rdf:resource="https://phaidra.vetmeduni.ac.at/o:4046"></dc:identifier>

  
<dc:language>en</dc:language>

  
<edm:type>TEXT</edm:type>

  
<dc:type>journal article</dc:type>

  
<dc:type>Wissenschaftlicher Artikel</dc:type>

  
<dc:type>Articolo di rivista</dc:type>

  
<dc:type xml:lang="it">Testo</dc:type>

  
<dc:type xml:lang="it">Articolo di rivista</dc:type>

  
<dc:type xml:lang="en">Text</dc:type>

  
<dc:type xml:lang="en">journal article</dc:type>

  
<dc:type xml:lang="de">Text</dc:type>

  
<dc:type xml:lang="de">Wissenschaftlicher Artikel</dc:type>

  
<dc:subject xml:lang="en">Animals</dc:subject>

  
<dc:subject xml:lang="en">Mesenchymal Stem Cells Metabolism</dc:subject>

  
<dc:subject xml:lang="en">YAP-Signaling Proteins Metabolism</dc:subject>

  
<dc:subject xml:lang="en">RNA-Binding Protein EWS Metabolism</dc:subject>

  
<dc:subject xml:lang="en">RNA-Binding Protein EWS Genetics</dc:subject>

  
<dc:subject xml:lang="en">Humans</dc:subject>

  
<dc:subject xml:lang="en">Mice</dc:subject>

  
<dc:subject xml:lang="en">Cell Transformation, Neoplastic Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Cell Transformation, Neoplastic Genetics</dc:subject>

  
<dc:subject xml:lang="en">Proto-Oncogene Protein c-fli-1Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Proto-Oncogene Protein c-fli-1Genetics</dc:subject>

  
<dc:subject xml:lang="en">Adaptor Proteins, Signal Transducing Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Insulin-Like Growth Factor I Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Transcription Factors Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Sarcoma, Ewing Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Sarcoma, Ewing Pathology</dc:subject>

  
<dc:subject xml:lang="en">Sarcoma, Ewing Genetics</dc:subject>

  
<dc:subject xml:lang="en">Cellular Reprogramming Drug Effects</dc:subject>

  
<dc:subject xml:lang="en">Oncogene Proteins, Fusion Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Oncogene Proteins, Fusion Genetics</dc:subject>

  
<dc:subject xml:lang="en">Receptor, IGF Type 1 Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Bone and Bones Metabolism</dc:subject>

  
<dc:subject xml:lang="en">Bone and Bones Pathology</dc:subject>

  
<dcterms:issued>2025</dcterms:issued>

  
<dc:date>2025</dc:date>

  
<dc:creator>Rahil Noorizadeh</dc:creator>

  
<dc:creator>Barbara Sax</dc:creator>

  
<dc:creator>Tahereh Javaheri</dc:creator>

  
<dc:creator>Branka Radic-Sarikas</dc:creator>

  
<dc:creator>Valerie Fock</dc:creator>

  
<dc:creator>Veveeyan Suresh</dc:creator>

  
<dc:creator>Maximilian Kauer</dc:creator>

  
<dc:creator>Aleksandr Bykov</dc:creator>

  
<dc:creator>Danijela Kurija</dc:creator>

  
<dc:creator>Michaela Schlederer</dc:creator>

  
<dc:creator>Lukas Kenner</dc:creator>

  
<dc:creator>Gerhard Weber</dc:creator>

  
<dc:creator>Wolfgang Mikulits</dc:creator>

  
<dc:creator>Florian Halbritter</dc:creator>

  
<dc:creator>Richard Moriggl</dc:creator>

  
<dc:creator>Heinrich Kovar</dc:creator>

  
<dc:publisher>Cell Press</dc:publisher>

  
<dcterms:isPartOf></dcterms:isPartOf>

  
</edm:ProvidedCHO>

  
<edm:WebResource rdf:about="https://phaidra.vetmeduni.ac.at/api/object/o:4046/get">
  
</edm:WebResource>

  
</rdf:RDF>


